Abstract
Cerebrospinal fluid (CSF) is a body fluid which has direct contact with the central nervous system, and as such, changes in its composition might be informative about various aspects of the brain. It has been postulated for quite a long time that proteomic analysis of CSF will reveal protein markers related to neurological disorders, their prognosis and early detection, efficacy of treatment, etc. Several proteomic profiling platforms provide tools to determine changes occurring in protein profiles of CSF reflecting physiological and pathological changes. Two major strategies are used. The first strategy is based on determining quantitative changes at the level of intact proteins followed by protein identification by tandem mass spectrometry of in-gel-digested protein spots. Usually, two-dimensional gel electrophoresis with DIGE technology is used. The second strategy is based on tryptic digestion of entire sample, labeling resulting peptides with mass tags and determining quantitative changes in protein content based on relative ratios of peptides. Typically iTRAQ® technology is used. Regardless of the strategy used, samples of CSF need to be simplified by removing most abundant proteins constituting more than 90% of a total pool of proteins. Detailed protocols are presented in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tsunoda, A., H. Mitsuoka, H. Bandai, T. Endo, H. Arai, and K. Sato. 2002. Intracranial cerebrospinal fluid measurement studies in suspected idiopathic normal pressure hydrocephalus, secondary normal pressure hydrocephalus, and brain atrophy. J Neurol Neurosurg Psychiatry 73, 552–555.
Silverberg, G. D., M. Mayo, T. Saul, J. Carvalho, and D. McGuire. 2004. Novel ventriculo-peritoneal shunt in Alzheimer’s disease cerebrospinal fluid biomarkers. Expert Rev Neurother 4, 97–107.
Wittke, S., H. Mischak, M. Walden, W. Kolch, T. Radler, and K. Wiedemann. 2005. Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis 26, 1476–1487.
Ogata, Y., M. C. Charlesworth, and D. C. Muddiman. 2005. Evaluation of protein depletion methods for the analysis of total-, phospho- and glycoproteins in lumbar cerebrospinal fluid. J Proteome Res 4, 837–845.
Johnston, I., and C. Teo. 2000. Disorders of CSF hydrodynamics. Childs Nerv Syst 16, 776–799.
Maurer, M. H. 2010. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Mass Spectrom Rev. 29, 17–28.
Yuan, X., and D. M. Desiderio. 2003. Proteomics analysis of phosphotyrosyl-proteins in human lumbar cerebrospinal fluid. J Proteome Res 2, 476–487.
Yuan, X., and D. M. Desiderio. 2005. Proteomics analysis of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 815, 179–189.
Rozek, W., M. Ricardo-Dukelow, S. Holloway, H. E. Gendelman, V. Wojna, L. Melendez, and P. Ciborowski. 2007. Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res 6, 4189–99.
Ciborowski, P. 2009. Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches. Biomark Med 3, 771–785.
Lucchi, G., J. B. Hendra, D. Pecqueur, and P. Ducoroy. 2007. [Towards a standardization of the tools for the studies of clinical proteomics]. Med Sci (Paris) Spec No 1, 19–22.
Oberg, A. L., D. W. Mahoney, J. E. Eckel-Passow, C. J. Malone, R. D. Wolfinger, E. G. Hill, L. T. Cooper, O. K. Onuma, C. Spiro, T. M. Therneau, and H. R. Bergen, 3 rd. 2008. Statistical analysis of relative labeled mass spectrometry data from complex samples using ANOVA. J Proteome Res 7, 225–233.
Storey, J. D., and R. Tibshirani. 2003. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100, 9440–9445.
Oh, J. H., S. Pan, J. Zhang, and J. Gao. 2010. MSQ: a tool for quantification of proteomics data generated by a liquid chromatography/matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry based targeted quantitative proteomics platform. Rapid Commun Mass Spectrom 24, 403–408.
Pan, S., J. Rush, E. R. Peskind, D. Galasko, K. Chung, J. Quinn, J. Jankovic, J. B. Leverenz, C. Zabetian, C. Pan, Y. Wang, J. H. Oh, J. Gao, J. Zhang, T. Montine, and J. Zhang. 2008. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res 7, 720–730.
Silberring, J., and P. Ciborowski. Biomarker discovery and clinical proteomics. Trends Analyt Chem 29, 128.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Pottiez, G., Ciborowski, P. (2012). Proteomic Profiling of Cerebrospinal Fluid. In: Karamanos, Y. (eds) Expression Profiling in Neuroscience. Neuromethods, vol 64. Humana Press. https://doi.org/10.1007/978-1-61779-448-3_13
Download citation
DOI: https://doi.org/10.1007/978-1-61779-448-3_13
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-447-6
Online ISBN: 978-1-61779-448-3
eBook Packages: Springer Protocols